Most cited papers from Vanquish Oncology (United States)
What are the most cited papers from Vanquish Oncology (United States)?
The most cited paper from Vanquish Oncology (United States) is "Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies" (Oana Cristina Danciu, Matthias Holdhoff, Richard A. Peterson et al., 2022), with 30 citations. Next come "The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma" (8) and "Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas" (7).
Showing 3 of 3 papers. Every paper is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies Oana Cristina Danciu, Matthias Holdhoff, Richard A. Peterson et al. · British Journal of Cancer | 5 Dec 2022 | 30 |
| 2 | The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma Matthew W. Boudreau, Emily J. Tonogai, Claire P. Schane et al. · Melanoma Research | 22 Sep 2023 | 8 |
| 3 | Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas Matthias Holdhoff, Martin Kelly Nicholas, Richard A. Peterson et al. · Neuro-Oncology Advances | 2023 | 7 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.